Literature DB >> 16341811

Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation.

M E Baser1, H Rai, A J Wallace, D G R Evans.   

Abstract

Neurofibromatosis 2 (NF2) is caused by inactivating mutations of the NF2 tumor suppressor gene. Somatic NF2 mutations also occur in a high proportion of human primary malignant mesotheliomas. We report an elderly man with NF2, malignant mesothelioma, and a constitutional NF2 missense mutation. The long latent period for mesothelioma in this patient (61 years) raises the possibility that the type of mutant NF2 allele could affect mesothelioma tumorigenesis or progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16341811     DOI: 10.1007/s10689-005-0659-8

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  11 in total

1.  Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation.

Authors:  J Q Cheng; W C Lee; M A Klein; G Z Cheng; S C Jhanwar; J R Testa
Journal:  Genes Chromosomes Cancer       Date:  1999-03       Impact factor: 5.006

2.  A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; D Teare; V Newton; T Strachan; R Ramsden; R Harris
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

Review 3.  Asbestos and mesothelioma: genetic lessons from a tragedy.

Authors:  A Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

Review 4.  The pathogenesis of mesothelioma.

Authors:  Michele Carbone; Robert A Kratzke; Joseph R Testa
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

5.  Predictors of the risk of mortality in neurofibromatosis 2.

Authors:  Michael E Baser; J M Friedman; Dana Aeschliman; Harry Joe; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2002-08-22       Impact factor: 11.025

6.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.

Authors:  A B Bianchi; S I Mitsunaga; J Q Cheng; W M Klein; S C Jhanwar; B Seizinger; N Kley; A J Klein-Szanto; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

7.  Demographic patterns for mesothelioma in the United States.

Authors:  R R Connelly; R Spirtas; M H Myers; C L Percy; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1987-06       Impact factor: 13.506

8.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.

Authors:  J A Trofatter; M M MacCollin; J L Rutter; J R Murrell; M P Duyao; D M Parry; R Eldridge; N Kley; A G Menon; K Pulaski
Journal:  Cell       Date:  1993-03-12       Impact factor: 41.582

9.  Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2.

Authors:  G A Rouleau; P Merel; M Lutchman; M Sanson; J Zucman; C Marineau; K Hoang-Xuan; S Demczuk; C Desmaze; B Plougastel
Journal:  Nature       Date:  1993-06-10       Impact factor: 49.962

10.  Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours.

Authors:  Jocelyne Fleury-Feith; Céline Lecomte; Annie Renier; Mireille Matrat; Laurence Kheuang; Vincent Abramowski; Françoise Levy; Anne Janin; Marco Giovannini; Marie-Claude Jaurand
Journal:  Oncogene       Date:  2003-06-12       Impact factor: 9.867

View more
  6 in total

Review 1.  Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.

Authors:  Min Hwan Kim; Joon Kim
Journal:  Cell Mol Life Sci       Date:  2016-11-08       Impact factor: 9.261

Review 2.  Advances in the treatment of neurofibromatosis-associated tumours.

Authors:  Andrew L Lin; David H Gutmann
Journal:  Nat Rev Clin Oncol       Date:  2013-08-13       Impact factor: 66.675

3.  Factors that impact susceptibility to fiber-induced health effects.

Authors:  Jennifer E Below; Nancy J Cox; Naomi K Fukagawa; Ari Hirvonen; Joseph R Testa
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

4.  Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.

Authors:  Anna-Mariya Kukuyan; Eleonora Sementino; Yuwaraj Kadariya; Craig W Menges; Mitchell Cheung; Yinfei Tan; Kathy Q Cai; Michael J Slifker; Suraj Peri; Andres J Klein-Szanto; Frank J Rauscher; Joseph R Testa
Journal:  Cancer Res       Date:  2019-05-31       Impact factor: 13.312

Review 5.  NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.

Authors:  Rebecca Dunbar Schroeder; Laura S Angelo; Razelle Kurzrock
Journal:  Oncotarget       Date:  2014-01-15

6.  Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival.

Authors:  Lisa Quetel; Clément Meiller; Jean-Baptiste Assié; Yuna Blum; Sandrine Imbeaud; François Montagne; Robin Tranchant; Julien de Wolf; Stefano Caruso; Marie-Christine Copin; Véronique Hofman; Laure Gibault; Cécile Badoual; Ecaterina Pintilie; Paul Hofman; Isabelle Monnet; Arnaud Scherpereel; Françoise Le Pimpec-Barthes; Jessica Zucman-Rossi; Marie-Claude Jaurand; Didier Jean
Journal:  Mol Oncol       Date:  2020-03-10       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.